Impact of menstrual cycle phases on C-reactive protein concentrations

Shilpi Vashishta, Sushila Gahlot, Anita Singh, Rajni Goyal


Background: C-reactive protein (CRP) is one of the most commonly employed indicator of acute phase reaction and predictors of cardiovascular disease in healthy women; although, only a sparse information on its variations during a regular menstrual cycle is currently available. Our objective was to see whether CRP levels are affected during different phases of menstrual cycle.

Methods: Females aged 15-45 years with regular menstrual cycle in terms of length, flow and variation from cycle to cycle were followed for one menstrual cycle. Serum levels of C-reactive protein were measured in the Follicular (10th day) and in the Luteal (22nd day) phase of the menstrual cycle.

Results: C-reactive protein levels were observed to vary in response to the phases of menstrual cycle. The concentrations of C-reactive protein levels tend to be highest during the Follicular phase and it declined significantly in the Luteal phase.

Conclusions: Identifying the fluctuations in C-reactive protein levels during the menstrual cycle is essential as there may be clinical implication of the suitable timing of assessment while framing and concluding studies in women of reproductive age.


C-reactive protein, Menstrual cycle, Predictor

Full Text:



Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2000;107(3):363-9.

Clearfield MBDO. C-Reactive protein: a new risk assessment tool for cardiovascular disease. JAOA. 2005;105(9):409-16.

Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108(16):1930-2.

Jain S, Gautam V, Naseem S. Acute-phase proteins: as diagnostic tool. J Pharmacy Bioallie Sci. 2011;3(1):118-27.

Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4):37S-42S.

Shende SS, Bimanpalli MV, Apte IC, Mahajan VV, Narkhede HP. Study of lipid profile and c reactive protein in pre- and post-menopausal women. J Clinic Diagnos Res. 2011;5(8):1544-7.

Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109(16):2016-22.

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107(3):391-7.

Ridker PM, Rifai N, Bradwin G, Buring JE. Non-HDL cholesterol, apolipopro-teins A-l and B100, standard lipid measures, lipid ratios, and CRP as risk fac-tors for cardiovascular disease in women. JAMA. 2005;294(3):326-33.

Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. Estrogen de-creases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest. 1999; 104(4):503-13.

Korpelainen EI, Gamble JR, Smith WB, Goodall GJ, Qiyu S, Woodcock JM et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci U S A. 1993;90(23):11137-41.

Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci. 2003;73(10):1245-52.

Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85(1):214-8.

Wander K, Brindle E and O’Connor KA. C - reactive protein across the Menstrual Cycle. Am J Physic Anthropol. 2008;136(2):138-46.

Speroff L, ‎Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia(USA): Lippincott Williams & Wilkins; 2005.

Price CP, Trull AK, Berry D, Gorman EG. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J Immunol Methods. 1987;99: 205-17.

Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, De Geyter C et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab. 2005;90(6):3230-5.

Gursoy A, Caglar G, Kiseli M, Pabuccu E, Candar T, Demirtas S. CRP at early follicular phase of menstrual cycle can cause misinterpretation for cardiovascular risk assessment. Interv Med Appl Sci. 2015;7(4):143-6.

Gaskins AJ, Wilchesky M, Mumford SL, Whitcomb BW, Browne RW, Wactawski-Wende J et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the biocycle study. Am J Epidemiol. 2012;175(5):423-31.

Jilma B, Dirnberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG et al. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med. 1997;130(1):69-75.

Wunder DM, Yared M, Bersinger NA, Widmer D, Kretschmer R, Birkhauser MH. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. Eur J Endocrinol. 2006,155(1):137-42.

Saxena AR, Seely EW, Goldfine AB. Cardiovascular risk factors and menstrual cycle phase in premenopausal women. J Endocrinol Invest. 2012;35( 8):715-9.

Gray GA, Sharif I, Webb DJ. Oestrogen and the car-diovascular system: the good, the bad and the puzzling. Trends Pharmacol Sci. 2001;22(3):152-6.

Lu A, Frink M, Choudhry MA, Schwacha MG, Hubbard WJ, Rue LW et al. Mitochondria play an important role in 17beta-estradiol attenuation of H2O2-induced rat endothelial cell apoptosis. Am J Physiol Endocrinol Metab. 2007;292(2):E585-93.

Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11(4):411-23.

Roberts CW, Walker W, Alexander J. Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev. 2001;14(3):476-88.